Skip to main content

Table 3 Change in IOP (mmHg) from baseline to week 4 (worse eye, ANCOVA, ITT population using LOCF)

From: A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

Latanoprost concentration (μg/mL)
  50 75 100 125
N 71 70 72 69
8 a.m. IOP
 LS mean change (mmHg)* −9.72 −9.49 −10.04 −9.23
 Adjusted difference in LS mean ± SEM   0.23 ± 0.58 −0.32 ± 0.58 0.49 ± 0.58
 (90% CI)   (−0.72, 1.19) (−1.27, 0.63) (−0.47, 1.45)
 p-value   0.657 0.289 0.802
4 p.m. IOP
 LS mean change (mmHg)* −8.47 −7.96 −8.84 −8.49
 Adjusted difference in LS mean ± SEM   0.51 ± 0.63 −0.36 ± 0.62 −0.02 ± 0.63
 (90% CI)   (−0.53, 1.55) (−1.39, 0.67) (−1.06, 1.02)
 p-value   0.792 0.280 0.488
  1. ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, ITT intent to treat, SEM standard error of the mean.
  2. *Adjusting for baseline IOP (covariate) with dose group and center as factors.
  3. Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
  4. One-sided p-value.